Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 2043-2048, 2006. First published September 21, 2006; 10.1373/clinchem.2006.073544
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.073544v1
52/11/2043    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pepe, G.
Right arrow Articles by Matà, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pepe, G.
Right arrow Articles by Matà, S.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2006;52:2043-2048.)
© 2006 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Lipoprotein(a) in the Cerebrospinal Fluid of Neurological Patients with Blood–Cerebrospinal Fluid Barrier Dysfunction

Gabriella Pepe1,2,a, Guglielmina Chimienti1, Grazia Maria Liuzzi1, Biagia Leila Lamanuzzi1, Marina Nardulli1, Francesco Lolli3, Eduardo Anglés-Cano4 and Sabrina Matà3

1 Department of Biochemistry and Molecular Biology, University of Bari.
2 Institute of Biomembrane and BioEnergetics of Bari, Consiglio Nazionale delle Ricerche, Italy.
3 Department of Neurology, University of Florence, Italy.
4 INSERM, Paris, France.

aAddress correspondence to this author at: Department of Biochemistry and Molecular Biology, University of Bari, via Orabona, 4-70126 Bari, Italy. Fax 39-08-05-44-3317; e-mail g.pepe{at}biologia.uniba.it.

Background: Lipoprotein(a) [Lp(a)] is a recognized pathogenic particle in human plasma, but its presence in the cerebrospinal fluid and its possible role in the central nervous system have not been documented. We tested the hypothesis that apolipoprotein(a) [apo(a)], free or as a component of the Lp(a) particle, can cross the blood–cerebrospinal fluid barrier and be found in the cerebrospinal fluid of patients affected by neurologic pathologies.

Methods: We studied paired cerebrospinal fluid/serum samples from 77 patients with inflammatory (n = 20) or noninflammatory (n = 34) blood–cerebrospinal fluid barrier dysfunction and without blood–cerebrospinal fluid barrier dysfunction (n = 23). We used ELISA to measure Lp(a) concentrations and Western blot and immunodetection to analyze apo(a) isoforms in native and reducing conditions.

Results: Entire Lp(a) with either small or large apo(a) isoforms was present in the cerebrospinal fluid of patients with blood–cerebrospinal fluid barrier dysfunction, regardless of its pathogenesis. Multiple linear regression analysis showed that both serum Lp(a) concentration (P = 0.003) and cerebrospinal fluid/serum albumin ratio (P <0.001) were predictors of the Lp(a) concentration in cerebrospinal fluid.

Conclusions: Our results demonstrate that Lp(a) can cross a dysfunctional blood–cerebrospinal fluid barrier. The unusual presence of Lp(a) in the cerebrospinal fluid could extend some of its known pathogenic effects to the central nervous system.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.